Leukemia-associated fusion proteins: Multiple mechanisms of action to drive cell transformation

Cell Cycle

Volumn 4, Issue 1, 2005, Pages 67-69

  Insinga, Alessandra ^a   Pelicci, Pier Giuseppe ^a,b   Minucci, Saveria ^a,c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Apoptosis; Leukemia; Mouse model; Oncogenic fusion protein; p53

Indexed keywords

ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; RETINOIC ACID RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; COLONY FORMING CELL; HUMAN; LEUKEMIA CELL; NONHUMAN; ONCOGENE; POSTTRANSCRIPTIONAL GENE SILENCING; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; REVIEW; STRESS;

EID: 17444372641     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.1.1400     Document Type: Review

References (31)

1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278:1059-64.
2. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372:143-149.
3. Rabbitts TH. Translocations, master genes, and differences between the origins of acute and chronic leukemias. Cell 1991; 67:641-4.
4. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396:643-9.
5. Westervelt P, Ley TJ. Seed versus soil: The importance of the target cell for transgenic models of human leukemias. Blood 1999; 93:2143-8.
6. Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A, Diverio D, Gasparini P, Capillo M, Colombo E, Matteucci C, Contegno F, Lo-Coco F, Scanziani E, Gobbi A, Pelicci PG. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoieric progenitors. Blood 2002; 100:2989-95.
7. He L, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, Pandolfi PP. Two critical hits for promyelocytic leukemia. Mol Cell 2000; 6:1131-41.
8. Kogan SC, Brown DE, Shultz DB, Truong BT, Lallemand-Breitenbach V, Guillemin MC, Lagasse E, Weissman IL, Bishop JM. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARα) to block neutrophil differentiation and initiate acute leukemia. J Exp Med 2001; 193:531-43.
9. Lin RJ, Egan DA, Evans RM. Molecular genetics of acute promyelocytic leukemia. Trends Genet 1999; 15:179-84.
10. Minucci S, Pelicci PG. Retinoid receptors in health and disease: Coregulators and the chromatin connection. Semin Cell Dev Biol 1999; 10:215-25.
11. Berger R, Le Coniat M, Derre J, Vecchione D, Jonveaux P. Cytogenetic studies in acute promyelocytic leukemia: A survey of secondary chromosomal abnormalities. Genes Chromosomes Cancer 1991; 3:332-7.
12. Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J, Powles RL, Catovsky D. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997; 96:314-21.
13. Zimonjic DB, Pollock JL, Westervelt P, Popescu NC, Ley TJ. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci USA 2000; 97:13306-11.
14. Longo L, Trecca D, Biondi A, Lo Coco F, Grignani F, Maiolo AT, Pelicci PG, Neri A. Frequency of RAS and p53 mutations in acute promyelocytic leukemias. Leuk Lymphoma 1993; 11:405-10.
15. Trecca D, Longo L, Biondi A, Cro L, Calori R, Grignani F, Maiolo AT, Pelicci PG, Neri A. Analysis of p53 gene mutations in acute myeloid leukemia. Am J Hematol 1994; 46:304-9.
16. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S, Pelicci PG. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391:815-8.
17. Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391:811-4.
18. Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 2001; 20:3110-5.
19. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268:2764-72.
20. Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Rev Cancer 2001; 1:233-9.
21. Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, Pelicci PG. Cell death induction by the acute promyelocytic leukemia-specific PML/RARalpha fusion protein. Proc Natl Acad Sci USA 1997; 94:10901-6.
22. Heimfeld S, Hudak S, Weissman I, Rennick D. The in vitro response of phenotypically defined mouse stem cells and myeloerythroid progenitors to single or multiple growth factors. Proc Natl Acad Sci USA 1991; 88:9902-6.
23. Morrison SJ, Wandycz AM, Hemmati HD, Wright DE, Weissman IL. Identification of a lineage of multipotent hematopoietic progenitors. Development 1997; 124:1929-39.
24. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241:58-62.
25. Gottifredi V, Prives C. P53 and PML: New partners in tumor suppression. Trends Cell Biol 2001; 11:184-7.
26. Pearson M, Pelicci PG. PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 2001; 20:7250-6.
27. Prives C, Manley J. Why is p53 acetylated? Cell 2001; 107:815-8.
28. Rego EM, Wang ZG, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP. Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med 2001; 193:521-9.
29. Marks P, Rifkind R, Richon V, Breslow R, Miller T, Kelly W. Histone deacetylases and cancer: Causes and therapies. Nature Rev Cancer 2001; 1:194-202.
30. Kelly WK, O'Connor OA. Marks PA. Histone deacetylase inhibitors: From target to clinical trials. Expert Opin Investig Drugs 2002; 11:1695-713.
31. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 2003; 4:13-8.